Daiichi Sankyo Ranbaxy Acquisition Very Much Alive
This article was originally published in The Pink Sheet Daily
Executive Summary
Details of tender offer at 40 percent premium revealed.
You may also be interested in...
As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.
As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
During the last few months, India's largest drug maker Ranbaxy has been in the news more than almost any other manufacturer. Ranbaxy settled patent disputes on two of the largest global drug brands, Lipitor and Nexium. The company's CEO Malvinder Singh sealed a "game-changer" deal with Japan's third largest drug maker Daiichi Sankyo and sold 34.8 percent of his personal and family stake for over $4 billion (PharmAsia News, June 11, 2008). And a U.S FDA investigation of Ranbaxy continues to heat up over allegations of good manufacturing practices deviations at one of the company's manufacturing sites in India (PharmAsia News, July 29, 2008). This week, PharmAsia News' India bureau sat down with Singh to get his take on the action.